References

1. 1 Carapetis JR. The Current Evidence of the Burden of Group A Streptococcal Disease. Geneva: World Health Organization, 2004.
2. 2 Carapetis JR, Steer AC, Mulholland EK, Weber M. The global burden of group A streptococcal diseases. Lancet Infect Dis. 2005;5:685–94.
3. 3 Carapetis JR. Rheumatic heart disease in developing countries. N Engl J Med. 2007;357:439–41.
4. 4 Otto CM. Valvular stenosis and valvular regurgitation. Textbook of Clinical Echocardiography, 3rd ed. Philadelphia: Elsevier Saunders, 2004. p. 281–328.
5. 5 Tibazarwa KB, Volmink JA, Mayosi BM. Incidence of acute rheumatic fever in the world: a systematic review of population-based studies. Heart. 2008;94(12):1534–40.
6. 6 Clur SA. Frequency and severity of rheumatic heart disease in the catchment area of Gauteng hospitals, 1993–1995. S Afr Med J. 2006;96(3 Pt 2):233–7.
7. 7 Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M. Burden of valvular heart diseases: a population-based study. Lancet. 2006;368(9540):1005–11.
8. 8 Perez de Isla L, Zamorano J, Quezada M, Almeria C, Rodrigo JL, Serra V, et al. Functional mitral regurgitation after a first non-ST-segment elevation acute coronary syndrome: contribution to congestive heart failure. Eur Heart J. 2007;28(23):2866–72.
9. 9 Ypenburg C, Lancellotti P, Tops LF, Boersma E, Bleeker GB, Holman ER, et al. Mechanism of improvement in mitral regurgitation after cardiac resynchronization therapy. Eur Heart J. 2008;29(6):757–65.
10. 10 Troughton RW, Asher CR, Klein PA. Pericarditis. Lancet. 2004;363(9410):717–27.
11. 11 Mayosi BM. Contemporary trends in the epidemiology and management of cardiomyopathy and pericarditis in sub-Saharan Africa. Heart. 2007;93(10):1176–83.
12. 12 Damasceno A, Mayosi BM, Sani M, Ogah OS, Mondo C, Ojji D, et al. The causes, treatment, and outcome of acute heart failure in 1006 Africans from 9 countries. Arch Intern Med. 2012;172(18):1386–94.
13. 13 Sliwa K, Wilkinson D, Hansen C, Ntyintyane L, Tibazarwa K, Becker A, et al. Spectrum of heart disease and risk factors in a black urban population in South Africa (the Heart of Soweto Study): a cohort study. Lancet. 2008;371(9616):915–22.
14. 14 Ntsekhe M, Mayosi BM. Tuberculous pericarditis with and without HIV. Heart Failure Reviews. 2013;18(3):367–73.
15. 15 Mayosi BM, Burgess LJ, Doubell AF. Tuberculous pericarditis. Circulation. 2005;112(23):3608–16.
16. 16 Mayosi BM, Wiysonge CS, Ntsekhe M, Gumedze F, Volmink JA, Maartens G, et al. Mortality in patients treated for tuberculous pericarditis in sub-Saharan Africa. S Afr Med J. 2008;98(1):36–40.
17. 17 Mutyaba AK, Balkaran S, Cloete R, du Plessis N, Badri M, Brink J, et al. Constrictive pericarditis requiring pericardiectomy at Groote Schuur Hospital, Cape Town, South Africa: causes and perioperative outcomes in the HIV era (1990–2012). J Thorac Cardiovasc Surg. 2014;148(6):3058–65 e1.
18. 18 Mayosi BM, Ntsekhe M, Volmink JA, Commerford PJ. Interventions for treating tuberculous pericarditis. Cochrane Database Syst Rev. 2002(4):CD000526.
19. 19 Ntsekhe M, Wiysonge C, Volmink JA, Commerford PJ, Mayosi BM. Adjuvant corticosteroids for tuberculous pericarditis: promising, but not proven. QJM. 2003;96(8):593–9.
20. 20 Critchley JA, Young F, Orton L, Garner P. Corticosteroids for prevention of mortality in people with tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis. 2013;13(3):223–37.
21. 21 Gupta A, Ahmad FJ, Ahmad F, Gupta UD, Natarajan M, Katoch V, et al. Efficacy of Mycobacterium indicus pranii immunotherapy as an adjunct to chemotherapy for tuberculosis and underlying immune responses in the lung. PLoS One. 2012;7(7):e39215.
22. 22 Mathur A, Mallia MB, Subramanian S, Banerjee S, Sarma HD, Kothari K, et al. Preparation and in vivo evaluation of (99 m)TcN-tertiary butyl xanthate as a potential myocardial agent. Appl Radiat Isot. 2006;64(6):663–7.
23. 23 Saini V, Raghuvanshi S, Talwar GP, Ahmed N, Khurana JP, Hasnain SE, et al. Polyphasic taxonomic analysis establishes Mycobacterium indicus pranii as a distinct species. PLoS One. 2009;4(7):e6263.
24. 24 Elliott AM, Halwiindi B, Bagshawe A, Hayes RJ, Luo N, Pobee JO, et al. Use of prednisolone in the treatment of HIV-positive tuberculosis patients. Q J Med. 1992;85(307–308):855–60.
25. 25 Elliott AM, Luzze H, Quigley MA, Nakiyingi JS, Kyaligonza S, Namujju PB, et al. A randomized, double-blind, placebo-controlled trial of the use of prednisolone as an adjunct to treatment in HIV-1-associated pleural tuberculosis. J Infect Dis. 2004;190(5):869–78.
26. 26 Mayosi BM, Ntsekhe M, Bosch J, Pogue J, Gumedze F, Badri M, et al. Rationale and design of the Investigation of the Management of Pericarditis (IMPI) trial: a 2 x 2 factorial randomized double-blind multicenter trial of adjunctive prednisolone and Mycobacterium w immunotherapy in tuberculous pericarditis. Am Heart J. 2013;165(2):109–15 e3.
27. 27 Thienemann F, Sliwa K, Rockstroh JK. HIV and the heart: the impact of antiretroviral therapy: a global perspective. Eur Heart J. 2013;34(46):3538–46.
28. 28 Joint United Nations Programme on HIV/AIDS (UNAIDS). Global Report: UNAIDS Report on the Global AIDS Epidemic 2013. UNAIDS, 2013.
29. 29 Becker AC, Sliwa K, Stewart S, Libhaber E, Essop AR, Zambakides CA, et al. Acute coronary syndromes in treatment-naïve black South Africans with human immunodeficiency virus infection. J Interv Cardiol. 2010;23(1):70–7.
30. 30 Khunnawat C, Mukerji S, Havlichek D, Jr., Touma R, Abela GS. Cardiovascular manifestations in human immunodeficiency virus-infected patients. Am J Cardiol. 2008;102(5):635–42.
31. 31 Ntsekhe M, Mayosi BM. Cardiac manifestations of HIV infection: an African perspective. Nat Clin Pract Cardiovasc Med. 2009;6(2):120–7.
32. 32 Reinsch N, Neuhaus K, Esser S, Potthoff A, Hower M, Brockmeyer NH, et al. Prevalence of cardiac diastolic dysfunction in HIV-infected patients: results of the HIV-HEART study. HIV Clin Trials. 2010;11(3):156–62.
33. 33 Vedanthan R, Fuster V. Cardiovascular disease in Sub-Saharan Africa: a complex picture demanding a multifaceted response. Nat Clin Pract Cardiovasc Med. 2008;5(9):516–7.
34. 34 Stewart S, Carrington M, Pretorius S, Methusi P, Sliwa K. Standing at the crossroads between new and historically prevalent heart disease: effects of migration and socio-economic factors in the Heart of Soweto cohort study. Eur Heart J. 2011;32(4):492–9.
35. 35 Stewart S, Libhaber E, Carrington M, Damasceno A, Abbasi H, Hansen C, et al. The clinical consequences and challenges of hypertension in urban-dwelling black Africans: insights from the Heart of Soweto Study. Int J Cardiol. 2011;146(1):22–7.
36. 36 Bijl M, Dieleman JP, Simoons M, van der Ende ME. Low prevalence of cardiac abnormalities in an HIV-seropositive population on antiretroviral combination therapy. J Acquir Immune Defic Syndr. 2001;27(3):318–20.
37. 37 World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. Revision. World Health Organization, 2006.
38. 38 Monsuez JJ, Escaut L, Teicher E, Charniot JC, Vittecoq D. Cytokines in HIV-associated cardiomyopathy. Int J Cardiol. 2007;120(2):150–7.
39. 39 Patel RC, Frishman WH. Cardiac involvement in HIV infection. Med Clin North Am. 1996;80(6):1493–512.
40. 40 Wu TC, Pizzorno MC, Hayward GS, Willoughby S, Neumann DA, Rose NR, et al. In situ detection of human cytomegalovirus immediate-early gene transcripts within cardiac myocytes of patients with HIV-associated cardiomyopathy. AIDS. 1992;6(8):777–85.
41. 41 Barbaro G. HIV-associated cardiomyopathy etiopathogenesis and clinical aspects. Herz. 2005;30(6):486–92.
42. 42 D.A.D. Study Group, Friis-Moller N, Reiss P, Sabin CA, Weber R, Monforte A, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356(17):1723–35.
43. 43 Mulligan K, Grunfeld C, Tai VW, Algren H, Pang M, Chernoff DN, et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr. 2000;23(1):35–43.
44. 44 Riddler SA, Smit E, Cole SR, Li R, Chmiel JS, Dobs A, et al. Impact of HIV infection and HAART on serum lipids in men. JAMA. 2003;289(22):2978–82.